Skip to main content

Table 2 Significant clinical variables associated with TMPRSS1 and TMPRSS3 mRNA expression

From: Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival

 

TMPRSS1 expressiona

TMPRSS3 expressiona

Clinical variable

n (%)

P

Median / IQR

n (%)

P

Median / IQR

Tumor type

 

0.002

  

NS

 

 Benign

16 (11.3)

 

0.27 / 0.57

23 (12.1)

 

0.98 / 0.56

 Malignant

125 (88.7)

 

0.96 / 2.10

167 (87.9)

 

0.92 / 1.74

Tumor grade

 

0.000015

  

0.0002

 

 I

24 (19.5)

0.000007b

2.03 / 2.74

28 (17.3)

0.016b

1.76 / 2.80

 II

51 (41.5)

NSc

1.67 / 2.41

74 (45.7)

NSc

1.29 / 2.03

 III

48 (39.0)

0.000004d

0.55 / 0.88

60 (37.0)

0.0001d

0.55 / 0.84

ER status

 

0.000003

  

0.0027

 

 Negative

40 (32.5)

 

0.45 / 0.84

50 (31.1)

 

0.55 / 0.84

 Positive

83 (67.5)

 

1.67 / 2.44

111 (68.9)

 

1.24 / 2.34

PR status

 

0.001

  

0.0076

 

 Negative

56 (45.5)

 

0.59 / 1.39

70 (43.5)

 

0.67 / 1.21

 Positive

67 (54.5)

 

1.53 / 2.57

91 (56.5)

 

1.32 / 2.41

HER2 status

 

0.001

  

0.017

 

 Negative

99 (83.9)

 

1.12 / 2.25

130 (84.4)

 

1.08 / 2.46

 Positive

19 (16.1)

 

0.35 / 0.75

24 (15.6)

 

0.58 / 0.89

ER/PR/HER2 status

 

0.001

  

NS

 

 Triple-negative

24 (20.3)

 

0.49 / 0.98

29 (19.2)

 

0.69 / 1.86

 Non-triple-negative

94 (79.7)

 

1.12 / 2.33

122 (80.8)

 

1.09 / 1.81

  1. IQR, Interquartile range; NS, Not significant
  2. aMann-Whitney U test was used for subgroups of two variables and Kruskal-Wallis test for subgroups of several variables
  3. bP value for comparing mRNA expression in benign tumors versus grade I tumors
  4. cP value for comparing mRNA expression in grade I tumors versus grade II tumors
  5. dP value for comparing mRNA expression in grade I tumors versus grade III tumors